Skip to main content
Figure 5 | Molecular Cancer

Figure 5

From: A nucleoside anticancer drug, 1-(3-C-ethynyl-β-D-ribo-pentofuranosyl)cytosine (TAS106), sensitizes cells to radiation by suppressing BRCA2 expression

Figure 5

Duration of the down-regulation of BRCA2 and Rad51 by TAS106 in A549 cells. Cells were pretreated with or without TAS106 (1 μM) for 24 h. They were irradiated (10 Gy) and incubated for the indicated times in the absence of TAS106. After incubation, cell extracts were analyzed by Western blotting using specific antibodies. Actin was used as a loading control. (A) X-irradiation alone and (B) X-irradiation after pretreatment with TAS106. Representative blots of three separate experiments are shown.

Back to article page